Integrated BioPharma, Inc. (INBP)
OTCMKTS · Delayed Price · Currency is USD
0.3327
+0.0127 (3.98%)
At close: Jan 30, 2026

Integrated BioPharma Income Statement

Millions USD. Fiscal year is Jul - Jun.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
53.4354.3550.3250.6756.2563.56
Revenue Growth (YoY)
4.72%8.02%-0.70%-9.91%-11.51%20.45%
Cost of Revenue
48.2248.7946.4346.6149.6954.08
Gross Profit
5.215.563.884.066.559.48
Selling, General & Admin
3.523.543.633.943.813.7
Operating Expenses
3.523.543.633.943.813.7
Operating Income
1.692.020.250.122.755.78
Interest Expense
-0.05-0.05-0.05-0.01-0.13-0.26
Interest & Investment Income
0.10.090.07---
Other Non Operating Income (Expenses)
00-0-0.010.010.06
EBT Excluding Unusual Items
1.752.060.270.12.635.59
Gain (Loss) on Sale of Investments
-----0.060
Gain (Loss) on Sale of Assets
----0.02-
Other Unusual Items
-----1.66
Pretax Income
1.752.060.270.12.67.25
Income Tax Expense
1.081.250.160.13-1.24-0.77
Net Income
0.670.810.11-0.033.848.01
Net Income to Common
0.670.810.11-0.033.848.01
Net Income Growth
56.28%621.43%---52.10%95.06%
Shares Outstanding (Basic)
313030303030
Shares Outstanding (Diluted)
313131303232
Shares Change (YoY)
1.02%0.95%3.08%-7.34%0.65%3.07%
EPS (Basic)
0.020.030.00-0.000.130.27
EPS (Diluted)
0.020.030.00-0.000.120.25
EPS Growth
54.06%635.32%---52.00%92.31%
Free Cash Flow
2.41.870.391.123.612.76
Free Cash Flow Per Share
0.080.060.010.040.110.09
Gross Margin
9.75%10.23%7.72%8.01%11.65%14.92%
Operating Margin
3.17%3.72%0.50%0.24%4.88%9.10%
Profit Margin
1.26%1.49%0.22%-0.07%6.82%12.61%
Free Cash Flow Margin
4.49%3.45%0.78%2.20%6.41%4.33%
EBITDA
22.340.560.473.086.12
EBITDA Margin
3.75%4.30%1.11%0.93%5.48%9.63%
D&A For EBITDA
0.310.320.310.350.340.34
EBIT
1.692.020.250.122.755.78
EBIT Margin
3.17%3.72%0.50%0.24%4.88%9.10%
Effective Tax Rate
61.69%60.81%58.21%134.00%--
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.